Neoplasm Recurrence, Local
"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Descriptor ID |
D009364
|
MeSH Number(s) |
C04.697.655 C23.550.727.655
|
Concept/Terms |
Neoplasm Recurrence, Local- Neoplasm Recurrence, Local
- Local Neoplasm Recurrences
- Locoregional Neoplasm Recurrence
- Recurrences, Local Neoplasm
- Neoplasm Recurrences, Local
- Recurrence, Local Neoplasm
- Recurrence, Locoregional Neoplasm
- Local Neoplasm Recurrence
- Neoplasm Recurrence, Locoregional
- Locoregional Neoplasm Recurrences
- Neoplasm Recurrences, Locoregional
- Recurrences, Locoregional Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".
This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 4 | 4 |
1996 | 1 | 4 | 5 |
1997 | 0 | 6 | 6 |
1998 | 1 | 7 | 8 |
1999 | 2 | 0 | 2 |
2000 | 4 | 7 | 11 |
2001 | 1 | 15 | 16 |
2002 | 7 | 5 | 12 |
2003 | 5 | 8 | 13 |
2004 | 8 | 12 | 20 |
2005 | 7 | 12 | 19 |
2006 | 10 | 13 | 23 |
2007 | 13 | 7 | 20 |
2008 | 11 | 4 | 15 |
2009 | 7 | 10 | 17 |
2010 | 17 | 18 | 35 |
2011 | 9 | 22 | 31 |
2012 | 11 | 5 | 16 |
2013 | 14 | 16 | 30 |
2014 | 21 | 11 | 32 |
2015 | 19 | 19 | 38 |
2016 | 13 | 13 | 26 |
2017 | 19 | 16 | 35 |
2018 | 20 | 21 | 41 |
2019 | 20 | 17 | 37 |
2020 | 19 | 28 | 47 |
2021 | 9 | 39 | 48 |
2022 | 6 | 44 | 50 |
2023 | 1 | 35 | 36 |
2024 | 17 | 18 | 35 |
2025 | 9 | 0 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.
-
Performance of Two-Phase Designs for the Time-to-Event Outcome and a Case Study Assessing the Relapse Risk Associated With B-ALL Subtypes. JCO Clin Cancer Inform. 2025 May; 9:e2400223.
-
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer. Clin Cancer Res. 2025 May 01; 31(9):1615-1624.
-
Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial. Clin Cancer Res. 2025 May 01; 31(9):1587-1595.
-
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. J Natl Cancer Inst. 2025 May 01; 117(5):889-897.
-
Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data. Cancer Treat Res Commun. 2025; 43:100921.
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025 May 02; 220:115381.
-
Optimizing Outcomes in Gallbladder Cancer: Identifying Predictors of Futile Up-Front Surgery in a Global Multi-center Study. Ann Surg Oncol. 2025 Jun; 32(6):4374-4382.
-
Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation. Clin Cancer Res. 2025 Feb 17; 31(4):697-706.
-
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after =2 prior therapies. Blood. 2025 Feb 13; 145(7):708-719.
-
Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial. Pediatr Blood Cancer. 2025 May; 72(5):e31584.